Regeneron Pharmaceuticals (REGN) - 26 Year Stock Split History
Historical stock splits for Regeneron Pharmaceuticals since 1991. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
|Medical||Medical - Biomedical and Genetics||$40.911B||$4.860B|
|Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma and has preclinical programs in other diseases and disorders. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrens.|